Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap

May 16 2017

• By Malcolm Spicer

GoldKeyInPuzzle_1200x675

Related Content

Bring Naloxone To Opioid Overdoses: FDA Crowd-Sources Smartphone Apps

Sep 23 2016

FDA To Tackle Critical Generics Issue In Switch Paradigm Debate

Mar 12 2012

Light Still On For Switches After Pfizer Pulls Plug On OTC <em>Lipitor</em>

Aug 03 2015

Room For Innovative Switches Could Lurk In Existing FDA Framework

Oct 29 2014

The Future Of OTCs: Self-Selection Meets Diagnostics, Genetic Personalization

May 16 2011

CDER Talks Switches, Monograph 'More Than Ever,' But Mum On Changes

May 23 2016

Related Companies

Pfizer Inc.

Sanofi

Eli Lilly and Company

Adapt Pharma Limited

Additional Topics

United States Prescription To OTC Switch Drug Approval Standards Regulation OTC Drugs Consumer

More from Approval Standards

More from Pathways & Standards

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window